Postmarketing Observational Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
Latest Information Update: 21 Oct 2020
Price :
$35 *
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms ADAPT
- Sponsors AbbVie
- 16 Oct 2020 Status changed from active, no longer recruiting to completed.
- 29 Jun 2020 Planned End Date changed from 8 Sep 2020 to 30 Sep 2020.
- 29 Jun 2020 Planned primary completion date changed from 8 Sep 2020 to 30 Sep 2020.